{"id":"W4327560927","doi":"10.1136/jitc-2022-005301","title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Internal medicine; FOXP3; Pharmacodynamics; Tolerability; Adverse effect; Granzyme; Gastroenterology; Pharmacokinetics; Immunology; Pharmacology; CD8; Oncology; Immunotherapy; Immune system; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000532248,0.0003603243,0.0009204836,0.0004517587,0.0005474468,0.00002479092,0.000588825,0.000136578,0.0002084956],"category_scores_gemma":[0.00005335502,0.0002035794,0.0001368261,0.00118125,0.0003089676,0.0002155643,0.0000349725,0.0006794462,0.000001612743],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001788102,"about_ca_system_score_gemma":0.0004636585,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004496781,"about_ca_topic_score_gemma":0.001754767,"domain_scores_codex":[0.9975213,0.0004276067,0.0009911531,0.0002898868,0.0001846634,0.0005854263],"domain_scores_gemma":[0.9980073,0.0002312062,0.0009016941,0.0004579772,0.0003836653,0.0000181793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3106728,0.00693133,0.347128,0.0001559295,0.002461212,0.00001468547,0.0181435,0.002702262,0.2931002,0.00001523232,0.0002515365,0.01842331],"study_design_scores_gemma":[0.1473778,0.02395586,0.7515235,0.001214829,0.0001030987,0.00004055515,0.003463372,0.00002473605,0.06649313,0.00002289621,0.005244932,0.0005352989],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954862,0.002035088,0.00001335972,0.0001050109,0.0004110629,0.001862023,0.00004541963,0.00002823904,0.00001361757],"genre_scores_gemma":[0.9973326,0.0004548757,0.00002625601,0.00004764674,0.00001636899,0.0002395652,0.00001554907,0.00008197156,0.001785217],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4043955,"threshold_uncertainty_score":0.8301725,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01289863678017111,"score_gpt":0.3175022932758785,"score_spread":0.3046036564957074,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}